From Congress to Clinic: A Post-JSMO Update on Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Watch a CME-certified webcast and download the slides from a live, expert-led webinar to learn about new agents targeting HER3 for the treatment of non-small-cell lung cancer, including review of recent data reported at JSMO 2023.

Share

Program Content

Activities

Targeting HER3 in NSCLC
Therapeutic Relevance of HER3 in EGFR TKI-Resistant NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 03, 2023

HER3 Agents in NSCLC
Current Investigational Treatments Targeting HER3 in EGFR-Positive Post-TKI NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 03, 2023

Activities

HER3 NSCLC Update
From Congress to Clinic: A Post-JSMO Update on Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2023

Expires: June 04, 2024

Activities

FAQs: Targeting HER3 in NSCLC
FAQs: Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 25, 2023

Faculty

cover img faculity

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

cover img faculity

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.